IP Verse

Low Frequency Glatiramer Acetate Therapy - EP3409286

The patent EP3409286 was granted to Yeda Research on Aug 12, 2020. The application was originally filed on Aug 19, 2010 under application number EP18179172A. The patent is currently recorded with a legal status of "Revoked".

EP3409286

YEDA RESEARCH
Application Number
EP18179172A
Filing Date
Aug 19, 2010
Status
Revoked
Nov 8, 2024
Grant Date
Aug 12, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SYNTHONMay 11, 2021HAMM & WITTKOPPADMISSIBLE
GENERICS UKAug 17, 2020GILL JENNINGS & EVERYADMISSIBLE

Patent Citations (19) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2002037848
DESCRIPTIONUS2002055466
DESCRIPTIONUS2002077278
DESCRIPTIONUS2003004099
DESCRIPTIONUS2005014694
DESCRIPTIONUS2009149541
DESCRIPTIONUS6514938
DESCRIPTIONWO0027417
DESCRIPTIONWO0160392
DESCRIPTIONWO0197846
DESCRIPTIONWO2009070298
OPPOSITIONEP2630962
OTHEREP1210115
OTHEREP2405749
OTHEREP2630962
OTHEREP2949335
OTHEREP3199172
OTHERUS2007161566
SEARCHUS2007161566

Non-Patent Literature (NPL) Citations (19) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- KANSARA V; MITRA A; WU Y, "Subcutaneous Delivery", Drug Deliv Technol, (20090600), vol. 9, no. 6, pages 38 - 42-
DESCRIPTION- LUCA DURELLI, J Neurol, (20030000), vol. 250-
DESCRIPTION- Physician's Desk Reference, Medical Economics Co., Inc., (20050000), page 3115-
DESCRIPTION- POSER et al., Neurology, (19830300), vol. 13, no. 3, pages 227 - 230-
DESCRIPTION- "Subjects must have a confirmed and documented MS diagnosis as defined by the Revised McDonald criteria", Ann Neurol, (20050000), vol. 58, pages 840 - 846-
DESCRIPTION- G. COMI et al., "European/Canadian Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Glatiramer Acetere on Magnetic Resonance Imaging-Measured Disease Activity and Burden in Patients with Relapsing Multiple Sclerosis", Ann. Neurol., (20010000), vol. 49, doi:doi:10.1002/ana.64, pages 290 - 297, XP009042363
OPPOSITION- Anonymous, "Antitrust: commission opens formal investigation into possible anticompetitive conduct of teva in relation to a blockbuster multiple sclerosis medicine", EUROPEAN COMMISSION - Press release, (20210304), pages 1 - 2, XP055806893-
OPPOSITION- Anonymous, "Is Severity of Adverse Events Affected by the Dose and Frequency of Glatiramer Acetate Treatment of Relapsing-Remitting Multiple Sclerosis", American Academy of Neurology Annual Meeting, (20160000), page 177, XP055806897-
OPPOSITION- Efthimios Dardiotis, Zisis Tsouris, Paraskevi Aslanidou, Athina-Maria Aloizou, Maria Sokratous, Antonios Provatas, Vasileios Siokas, Georgia Deretzi & Georgios M. Hadjigeorgiou, "Body mass index in patients with Multiple Sclerosis: a meta-analysis", Neurological Research, (20190000), vol. 41, no. 9, pages 836 - 846, XP055806884-
OPPOSITION- Jerry S Wolinsky; Erik Borresen T; Dennis W Dietrich; Daniel Wynn; Yulia Sidi; Joshua R Steinerman; Volker Knappertz; Scott Kolodny, "GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis", Mult. Scler. Relat. Disord., (20150000), vol. 4, no. 4, pages 370 - 376, XP055473190
OTHER- DR. KLINGER, "the inventor of the 40mg, thrice-weekly GA dosage form, admitted that the patents-in-suit provided no clinical or pre-clinical data to support a 40mg dose of GA administered three times a week", Trial r., vol. 198, pages 14 - 20-
SEARCH- Anonymous, "Teva Provides Update on FORTE Trial", (20080707), Internet, URL: http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=1554743, (20150831), XP002743817 [A] 1-4 * abstract *-
SEARCH- CAON CHRISTINA ET AL, "Randomized, Prospective, Rater-Blinded, Four Year Pilot Study To Compare the Effect of Daily Versus Every Other Day Glatiramer Acetate 20 mg Subcutaneous Injections in RRMS", NEUROLOGY, & 61ST ANNUAL MEETING OF AMERICAN-ACADEMY-OF-NEUROLOGY; SEATTLE, WA, USA; APRIL 28 -29, 2009, (200903), vol. 72, no. 11, Suppl. 3, ISSN 0028-3878, page A317, XP009161100 [A] 1-4 * abstract *-
SEARCH- KHAN O ET AL, "Randomized, prospective, rater-blinded, four-year, pilot study to compare the effect of daily versus every - other - day injections in relapsing -remitting multiple", MULT.SCLER. (14, SUPPL. 1, S296, 2008) 0 REF. ISSN: 1352-4585 AV - WAYNE STATE UNIV, SCH MED, DETROIT, MI, USA., (2008), XP009161078 [A] 1-4 * abstract *-
SEARCH- YONG WEE V ET AL, "Immunological Responses to Different Doses of Glatiramer Acetate in MS: Analyses from the FORTE Trial", NEUROLOGY, & 61ST ANNUAL MEETING OF AMERICAN-ACADEMY-OF-NEUROLOGY; SEATTLE, WA, USA; APRIL 28 -29, 2009, (200903), vol. 72, no. 11, Suppl. 3, ISSN 0028-3878, page A39, XP002743818 [A] 1-4 * abstract *-
SEARCH- FLECHTER S ET AL, "Comparison of glatiramer acetate (Copaxone(R)) and interferon beta-1b (Betaferon(R)) in multiple sclerosis patients: An open-label 2-year follow-up", JOURNAL OF THE NEUROLOGICAL SCIENCES, (20020515), vol. 197, no. 1-2, ISSN 0022-510X, pages 51 - 55, XP002679780 [A] 1-4 * abstract *
SEARCH- FLECHTER SHLOMO ET AL, "Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration.", CLINICAL NEUROPHARMACOLOGY 2002 JAN-FEB LNKD- PUBMED:11852290, (200201), vol. 25, no. 1, ISSN 0362-5664, pages 11 - 15, XP009161076 [A] 1-4 * abstract * * "Comparison of daily with alternate-day treatment" on page 14 and "Drug Supply" on page 12 *
SEARCH- COHEN J A ET AL, "Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.", NEUROLOGY 20 MAR 2007 LNKD- PUBMED:17372130, (20070320), vol. 68, no. 12, ISSN 1526-632X, pages 939 - 944, XP002679784 [A] 1-4 * abstract *
SEARCH- SIMPSON DENE ET AL, "Glatiramer acetate: A review of its use in relapsing-remitting multiple sclerosis.", CNS DRUGS, (2002), vol. 16, no. 12, ISSN 1172-7047, pages 825 - 850, XP009161077 [A] 1-4 * "Therapeutic efficacy" on page 835 and "Dosage and Administration" on page 844 * * table II *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents